
EquitySector - HealthcareVery High Risk
Regular
NAV (27-Feb-26)
Returns (Since Inception)
Fund Size
₹492 Cr
Expense Ratio
2.38%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+16.15%
+13.70% (Cat Avg.)
Since Inception
+17.47%
— (Cat Avg.)
| Equity | ₹485.27 Cr | 98.66% |
| Others | ₹6.59 Cr | 1.34% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹52.73 Cr | 10.72% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹44.81 Cr | 9.11% |
| Divi's Laboratories Ltd | Equity | ₹26.94 Cr | 5.48% |
| Fortis Healthcare Ltd | Equity | ₹26.2 Cr | 5.33% |
| Lupin Ltd | Equity | ₹25.36 Cr | 5.16% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹24.1 Cr | 4.90% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹22.22 Cr | 4.52% |
| Laurus Labs Ltd | Equity | ₹21.69 Cr | 4.41% |
| Cash Offset For Derivatives | Cash - General Offset | ₹-16.76 Cr | 3.41% |
| Alkem Laboratories Ltd | Equity | ₹16.5 Cr | 3.36% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹13.32 Cr | 2.71% |
| Net Receivables / (Payables) | Cash - Collateral | ₹12.69 Cr | 2.58% |
| Ajanta Pharma Ltd | Equity | ₹12.6 Cr | 2.56% |
| Neuland Laboratories Ltd | Equity | ₹11.05 Cr | 2.25% |
| Sai Life Sciences Ltd | Equity | ₹10.08 Cr | 2.05% |
| Corona Remedies Ltd | Equity | ₹9.98 Cr | 2.03% |
| Acutaas Chemicals Ltd | Equity | ₹9.67 Cr | 1.97% |
| Narayana Hrudayalaya Ltd | Equity | ₹9.48 Cr | 1.93% |
| Shaily Engineering Plastics Ltd | Equity | ₹9.33 Cr | 1.90% |
| Abbott India Ltd | Equity | ₹8.76 Cr | 1.78% |
| Navin Fluorine International Ltd | Equity | ₹8.35 Cr | 1.70% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹8.25 Cr | 1.68% |
| Emcure Pharmaceuticals Ltd | Equity | ₹7.65 Cr | 1.55% |
| AstraZeneca Pharma India Ltd | Equity | ₹7.61 Cr | 1.55% |
| Pfizer Ltd | Equity | ₹7.34 Cr | 1.49% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹6.68 Cr | 1.36% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹6.65 Cr | 1.35% |
| Strides Pharma Science Ltd | Equity | ₹6.46 Cr | 1.31% |
| Aether Industries Ltd | Equity | ₹6.04 Cr | 1.23% |
| Thyrocare Technologies Ltd | Equity | ₹5.07 Cr | 1.03% |
| Aarti Pharmalabs Ltd | Equity | ₹5.02 Cr | 1.02% |
| Dr. Reddy's Laboratories Limited | Equity - Future | ₹4.81 Cr | 0.98% |
| Sudeep Pharma Ltd | Equity | ₹4.8 Cr | 0.98% |
| Supriya Lifescience Ltd | Equity | ₹4.6 Cr | 0.94% |
| Divi's Laboratories Limited | Equity - Future | ₹4.43 Cr | 0.90% |
| Zota Health Care Ltd | Equity | ₹4.26 Cr | 0.87% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹4.04 Cr | 0.82% |
| 12/03/2026 Maturing 91 DTB | Bond - Gov't/Treasury | ₹3.98 Cr | 0.81% |
| Cipla Ltd | Equity | ₹3.96 Cr | 0.80% |
| Ipca Laboratories Ltd | Equity | ₹3.84 Cr | 0.78% |
| Poly Medicure Ltd | Equity | ₹2.93 Cr | 0.60% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹2.92 Cr | 0.59% |
| Shilpa Medicare Ltd | Equity | ₹2.39 Cr | 0.49% |
| Mankind Pharma Limited | Equity - Future | ₹2.29 Cr | 0.47% |
| Anthem Biosciences Ltd | Equity | ₹2.07 Cr | 0.42% |
| 19/02/2026 Maturing 182 DTB | Bond - Gov't/Treasury | ₹2.05 Cr | 0.42% |
| Apollo Hospitals Enterprise Limited | Equity - Future | ₹1.65 Cr | 0.34% |
| Orchid Pharma Ltd | Equity | ₹1.56 Cr | 0.32% |
| Sun Pharmaceutical Industries Limited | Equity - Future | ₹1.45 Cr | 0.29% |
| Max Healthcare Institute Limited | Equity - Future | ₹1.26 Cr | 0.26% |
| Mankind Pharma Ltd | Equity | ₹1.2 Cr | 0.24% |
| 12/02/2026 Maturing 182 DTB | Bond - Gov't/Treasury | ₹1 Cr | 0.20% |
| 19/03/2026 Maturing 364 DTB | Bond - Gov't/Treasury | ₹0.99 Cr | 0.20% |
| 19/02/2026 Maturing 91 DTB | Bond - Gov't/Treasury | ₹0.94 Cr | 0.19% |
| Fortis Healthcare Limited | Equity - Future | ₹0.86 Cr | 0.17% |
| 19/03/2026 Maturing 182 DTB | Bond - Gov't/Treasury | ₹0.7 Cr | 0.14% |
| 364 Days Tbill Red 05-02-2026 | Bond - Gov't/Treasury | ₹0.4 Cr | 0.08% |
| 26/02/2026 Maturing 91 DTB | Bond - Gov't/Treasury | ₹0.4 Cr | 0.08% |
| 09/04/2026 Maturing 182 DTB | Bond - Gov't/Treasury | ₹0.2 Cr | 0.04% |
Large Cap Stocks
26.42%
Mid Cap Stocks
23.40%
Small Cap Stocks
45.43%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹435.12 Cr | 88.47% |
| Basic Materials | ₹33.39 Cr | 6.79% |
Standard Deviation
This fund
--
Cat. avg.
16.18%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.91
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.60
Higher the better

Since February 2024

Since February 2024
Since May 2025
Since February 2024
Since January 2025
ISIN INF03VN01878 | Expense Ratio 2.38% | Exit Load 1.00% | Fund Size ₹492 Cr | Age 2 years | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹31,996 Cr
Address
1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City, Mumbai
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments